[{"orgOrder":0,"company":"Isotopia","sponsor":"Philochem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"177-Lu OncoFAP-23","moa":"FAP","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotopia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isotopia \/ Philochem","highestDevelopmentStatusID":"4","companyTruncated":"Isotopia \/ Philochem"},{"orgOrder":0,"company":"Isotopia","sponsor":"Seibersdorf Labor GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Isotopia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotopia \/ Seibersdorf Labor GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Isotopia \/ Seibersdorf Labor GmbH"},{"orgOrder":0,"company":"Isotopia","sponsor":"CPDC Centre for Probe Development and Commercialization","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Isotopia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotopia \/ CPDC Centre for Probe Development and Commercialization","highestDevelopmentStatusID":"1","companyTruncated":"Isotopia \/ CPDC Centre for Probe Development and Commercialization"}]

Find Clinical Drug Pipeline Developments & Deals by Isotopia

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : 177Lu-OncoFAP-23 exhibits, in pre-clinical models, a very high and selective tumor uptake and with a significantly extended residence time at the site of disease, compared to other 177Lu-FAP-ligands.

                          Product Name : 177-Lu OncoFAP-23

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 13, 2022

                          Lead Product(s) : 177-Lu OncoFAP-23

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Philochem

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Lead Product(s) : n.c.a. 177-Lu

                          Therapeutic Area : Oncology

                          Study Phase : Undisclosed

                          Sponsor : CPDC Centre for Probe Development and Commercialization

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : 177Lu n.c.a (No-carrier-added Lutetium-177) is a very versatile isotope, and worldwide numerous clinical trials are being held, studying the effects of this isotope, used radiometal for targeted radiotherapy.

                          Product Name : n.c.a. 177-Lu

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 06, 2022

                          Lead Product(s) : n.c.a. 177-Lu

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : CPDC Centre for Probe Development and Commercialization

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Seibersdorf Labor, a GMP Contract manufacturing of radiopharmaceuticals, a global leader in the development, production, and commercialization of radiopharmaceuticals, will produce 177Lu n.c.a in collaboration with Isotopia Molecular Imaging for distribu...

                          Product Name : n.c.a. 177-Lu

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 18, 2021

                          Lead Product(s) : n.c.a. 177-Lu

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Seibersdorf Labor GmbH

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank